STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

RegulatoryrejectedAkeso/Summit lung cancer drugTavneosNegative

AI Analysis

Summary

Akeso and Summit's lung cancer drug shows worsening tumor-progression benefit, while AstraZeneca's Tavneos was withdrawn from Europe due to trial integrity concerns and pricing issues.

Outcome Details

Europe pulled Tavneos over trial integrity concerns

Importance:5/10

Sentiment:

-0.60

lung cancerhypertensionregulatory withdrawaltrial integritypricing concerns

Related Companies

$AZN

Read the original article

Published by STAT News on August 17, 2026 1:38 PM

Read Original